COVID-19 as a catalyst for reimagining cervical cancer prevention

Author:

Luckett Rebecca1ORCID,Feldman Sarah2ORCID,Woo Yin Ling3ORCID,Moscicki Anna-Barbara4,Giuliano Anna R5,de Sanjosé Silvia67ORCID,Kaufmann Andreas M8910ORCID,Leung Shuk On Annie11,Garcia Francisco12,Chan Karen13,Bhatla Neerja14,Stanley Margaret15ORCID,Brotherton Julia16,Palefsky Joel17ORCID,Garland Suzanne18,

Affiliation:

1. Beth Israel Deaconess Medical Center, Harvard Medical School

2. Brigham and Women’s Hospital, Harvard Medical School

3. University of Malaya

4. University of California, Los Angeles

5. H Lee Moffitt Cancer Center and Research Institute

6. National Cancer Institute

7. ISGlobal

8. Charité - Universitätsmedizin Berlin

9. Freie Universität Berlin

10. Humboldt Universität zu Berlin

11. McGill University Health Centre

12. Pima County

13. University of Hong Kong

14. All India Institute of Medical Sciences

15. University of Cambridge

16. Australian Centre for the Prevention of Cervical Cancer

17. University of California, San Francisco

18. Melbourne Medical School, Royal Women’s Hospital

Abstract

Cervical cancer has killed millions of women over the past decade. In 2019 the World Health Organization launched the Cervical Cancer Elimination Strategy, which included ambitious targets for vaccination, screening, and treatment. The COVID-19 pandemic disrupted progress on the strategy, but lessons learned during the pandemic – especially in vaccination, self-administered testing, and coordinated mobilization on a global scale – may help with efforts to achieve its targets. However, we must also learn from the failure of the COVID-19 response to include adequate representation of global voices. Efforts to eliminate cervical cancer will only succeed if those countries most affected are involved from the very start of planning. In this article we summarize innovations and highlight missed opportunities in the COVID response, and make recommendations to leverage the COVID experience to accelerate the elimination of cervical cancer globally.

Funder

National Cancer Institute

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3